Last Updated: November 8, 2026

Details for New Drug Application (NDA): 209388

NDA 209388 describes GIMOTI, which is a drug marketed by Qol Medcl and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the GIMOTI profile page.

The generic ingredient in GIMOTI is metoclopramide hydrochloride. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

Summary for 209388

Tradename:	GIMOTI
Applicant:	Qol Medcl
Ingredient:	metoclopramide hydrochloride
Patents:	7

Pharmacology for NDA: 209388

Mechanism of Action	Dopamine D2 Antagonists

Medical Subject Heading (MeSH) Categories for 209388

Antiemetics
Dopamine D2 Receptor Antagonists

Suppliers and Packaging for NDA: 209388

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388	NDA	Evoke Pharma, Inc.	72089-307	72089-307-15	1 BOTTLE, PUMP in 1 CARTON (72089-307-15) / 9.8 mL in 1 BOTTLE, PUMP

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SPRAY, METERED;NASAL			Strength	EQ 15MG BASE/SPRAY
Approval Date:	Jun 19, 2020	TE:		RLD:	Yes
Patent:	11,020,361	Patent Expiration:	Dec 22, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
Patent:	11,628,150	Patent Expiration:	Dec 22, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
Patent:	11,813,231	Patent Expiration:	Dec 22, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS

Expired US Patents for NDA 209388

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020	6,770,262	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.